Callahan Advisors LLC Sells 86,079 Shares of Pfizer Inc. $PFE

Callahan Advisors LLC lessened its stake in Pfizer Inc. (NYSE:PFE) by 12.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 627,718 shares of the biopharmaceutical company’s stock after selling 86,079 shares during the period. Pfizer comprises 1.3% of Callahan Advisors LLC’s portfolio, making the stock its 26th biggest holding. Callahan Advisors LLC’s holdings in Pfizer were worth $15,630,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the stock. Triad Wealth Partners LLC lifted its stake in shares of Pfizer by 1.9% in the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after buying an additional 386 shares during the period. ETF Store Inc. lifted its stake in shares of Pfizer by 3.8% in the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after buying an additional 396 shares during the period. Mattern Wealth Management LLC lifted its stake in shares of Pfizer by 4.6% in the fourth quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock valued at $228,000 after buying an additional 400 shares during the period. Pines Wealth Management LLC lifted its stake in shares of Pfizer by 4.4% in the fourth quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock valued at $235,000 after buying an additional 400 shares during the period. Finally, Pathway Financial Advisers LLC lifted its stake in shares of Pfizer by 0.9% in the fourth quarter. Pathway Financial Advisers LLC now owns 46,380 shares of the biopharmaceutical company’s stock valued at $1,155,000 after buying an additional 403 shares during the period. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on PFE. CICC Research began coverage on shares of Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price for the company. Wolfe Research reiterated an “underperform” rating and issued a $26.00 target price on shares of Pfizer in a research note on Thursday, May 14th. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. UBS Group increased their price target on shares of Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research report on Monday, April 13th. Finally, Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $28.61.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer advanced its new 25-strain pneumococcal vaccine into pivotal testing after strong Phase 2 infant data showed a much stronger immune response than Prevnar 20, raising the chance of a future growth driver. Reuters article
• Positive Sentiment: Pfizer also highlighted long-term oncology expansion around Padcev, biosimilars, and late-stage pipeline assets, which could help offset pressure from legacy drugs and improve future revenue visibility. Zacks article
• Neutral Sentiment: Several articles repeated the same pipeline themes, reinforcing investor attention on vaccine and oncology programs rather than introducing entirely new developments. Business Wire article
• Neutral Sentiment: One commentary piece compared Pfizer’s dividend and valuation profile with Johnson & Johnson, noting PFE’s low valuation and high yield but also weaker consistency versus JNJ; this may support income-focused investors, but it is not a direct operating catalyst. Seeking Alpha article
• Negative Sentiment: The J&J comparison underscores ongoing concerns about Pfizer’s relative growth consistency, suggesting the stock may still trade at a discount until management proves the pipeline can deliver more durable earnings growth. Seeking Alpha article

Pfizer Stock Performance

NYSE:PFE opened at $25.78 on Thursday. Pfizer Inc. has a 12-month low of $22.81 and a 12-month high of $28.75. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $146.91 billion, a PE ratio of 19.68 and a beta of 0.35. The firm has a 50-day moving average price of $26.91 and a 200 day moving average price of $26.22.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. During the same quarter in the prior year, the business posted $0.92 earnings per share. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.